Key immunological biomarkers such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) are widely used to predict responsiveness to immune checkpoint inhibitors (ICIs) (30, 31). Here, CD274 is linked to neoplasm.